Status:
RECRUITING
Screening for Alpha-1 Antitrypsin Deficiency in Patients With Airway Obstruction
Lead Sponsor:
Muğla Sıtkı Koçman University
Collaborating Sponsors:
PROGENIKA BIOPHARMA, A GRIFOLS Company
Conditions:
Alpha 1-antitrypsin Deficiency (AATD)
Eligibility:
All Genders
18+ years
Brief Summary
Brief Summary: This study aims to find out if a genetic condition called Alpha-1 Antitrypsin Deficiency (AATD) is more common in people who have shortness of breath and signs of airway obstruction on...
Detailed Description
1. Study Objectives and Rationale Alpha-1 Antitrypsin Deficiency (AATD) is a significantly underdiagnosed hereditary disorder that predisposes individuals to early-onset emphysema and chronic obstruct...
Eligibility Criteria
Inclusion
- Achieve a post-bronchodilator FEV1/FVC ratio of 70 or above in the respiratory function test.
- Be able to speak and understand Turkish.
- Have the mental and cognitive capacity to understand the questions asked.
Exclusion
- Renal dysfunction; acute inflammation; rheumatological, haematological, or liver diseases; COPD; asthma; bronchiectasis; and a history of malignancy.
- Pregnant women and users of oral contraceptives.
Key Trial Info
Start Date :
August 6 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 5 2026
Estimated Enrollment :
734 Patients enrolled
Trial Details
Trial ID
NCT07152834
Start Date
August 6 2025
End Date
January 5 2026
Last Update
September 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Muğla Training and Research Hospital
Muğla, Menteşe, Turkey (Türkiye), 48000